These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36552969)

  • 21. Quantitative Susceptibility Mapping of Amyloid-β Aggregates in Alzheimer's Disease with 7T MR.
    Tiepolt S; Schäfer A; Rullmann M; Roggenhofer E; ; Gertz HJ; Schroeter ML; Patt M; Bazin PL; Jochimsen TH; Turner R; Sabri O; Barthel H
    J Alzheimers Dis; 2018; 64(2):393-404. PubMed ID: 29865069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unsupervised resolution-agnostic quantitative susceptibility mapping using adaptive instance normalization.
    Oh G; Bae H; Ahn HS; Park SH; Moon WJ; Ye JC
    Med Image Anal; 2022 Jul; 79():102477. PubMed ID: 35605505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI-based quantitative susceptibility mapping (QSM) and R2* mapping of liver iron overload: Comparison with SQUID-based biomagnetic liver susceptometry.
    Sharma SD; Fischer R; Schoennagel BP; Nielsen P; Kooijman H; Yamamura J; Adam G; Bannas P; Hernando D; Reeder SB
    Magn Reson Med; 2017 Jul; 78(1):264-270. PubMed ID: 27509836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron Imaging as a Diagnostic Tool for Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Pyatigorskaya N; Sanz-Morère CB; Gaurav R; Biondetti E; Valabregue R; Santin M; Yahia-Cherif L; Lehéricy S
    Front Neurol; 2020; 11():366. PubMed ID: 32547468
    [No Abstract]   [Full Text] [Related]  

  • 25. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of iron deposition in brain basal ganglia of patients with Parkinson's disease using quantitative susceptibility mapping.
    Shahmaei V; Faeghi F; Mohammdbeigi A; Hashemi H; Ashrafi F
    Eur J Radiol Open; 2019; 6():169-174. PubMed ID: 31065578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. APART-QSM: An improved sub-voxel quantitative susceptibility mapping for susceptibility source separation using an iterative data fitting method.
    Li Z; Feng R; Liu Q; Feng J; Lao G; Zhang M; Li J; Zhang Y; Wei H
    Neuroimage; 2023 Jul; 274():120148. PubMed ID: 37127191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simulated and experimental phantom data for multi-center quality assurance of quantitative susceptibility maps at 3 T, 7 T and 9.4 T.
    Gustavo Cuña E; Schulz H; Tuzzi E; Biagi L; Bosco P; García-Fontes M; Mattos J; Tosetti M; Engelmann J; Scheffler K; Hagberg GE
    Phys Med; 2023 Jun; 110():102590. PubMed ID: 37116389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of liver iron concentration using the apparent susceptibility of hepatic vessels.
    Liu S; Wang C; Zhang X; Zuo P; Hu J; Haacke EM; Ni H
    Quant Imaging Med Surg; 2018 Mar; 8(2):123-134. PubMed ID: 29675354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developmental trajectory of magnetic susceptibility in the healthy rhesus macaque brain.
    Wu J; Peng S; Zhang Y; Pan B; Chen H; Hu X; Gong NJ
    NMR Biomed; 2022 Sep; 35(9):e4750. PubMed ID: 35474524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential applications of the quantitative susceptibility mapping (QSM) in MR-guided radiation therapy.
    Nosrati R; Paudel M; Ravi A; Pejovic-Milic A; Morton G; Stanisz GJ
    Phys Med Biol; 2019 Jul; 64(14):145013. PubMed ID: 31151120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: Interpreting positive susceptibility and the presence of iron.
    Wisnieff C; Ramanan S; Olesik J; Gauthier S; Wang Y; Pitt D
    Magn Reson Med; 2015 Aug; 74(2):564-70. PubMed ID: 25137340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining
    Liao H; Cai Z; Ye H; Chen Q; Zhang Y; Shaghaghi M; Lutz SE; Chen W; Cai K
    Front Neurosci; 2022; 16():1105376. PubMed ID: 36711150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Echo-time dependency of quantitative susceptibility mapping reproducibility at different magnetic field strengths.
    Lancione M; Donatelli G; Cecchi P; Cosottini M; Tosetti M; Costagli M
    Neuroimage; 2019 Aug; 197():557-564. PubMed ID: 31075389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain iron assessment in patients with First-episode schizophrenia using quantitative susceptibility mapping.
    Xu M; Guo Y; Cheng J; Xue K; Yang M; Song X; Feng Y; Cheng J
    Neuroimage Clin; 2021; 31():102736. PubMed ID: 34186296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multimodal comparisons of QSM and PET in neurodegeneration and aging.
    Cogswell PM; Fan AP
    Neuroimage; 2023 Jun; 273():120068. PubMed ID: 37003447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative susceptibility mapping and R1 measurement: Determination of the myelin volume fraction in the aging ex vivo rat corpus callosum.
    Cho H; Lee H; Gong Y; Kim YR; Cho J; Cho HJ
    NMR Biomed; 2022 Mar; 35(3):e4645. PubMed ID: 34739153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerating quantitative susceptibility and R2* mapping using incoherent undersampling and deep neural network reconstruction.
    Gao Y; Cloos M; Liu F; Crozier S; Pike GB; Sun H
    Neuroimage; 2021 Oct; 240():118404. PubMed ID: 34280526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QSMxT: Robust masking and artifact reduction for quantitative susceptibility mapping.
    Stewart AW; Robinson SD; O'Brien K; Jin J; Widhalm G; Hangel G; Walls A; Goodwin J; Eckstein K; Tourell M; Morgan C; Narayanan A; Barth M; Bollmann S
    Magn Reson Med; 2022 Mar; 87(3):1289-1300. PubMed ID: 34687073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy.
    Cushing CM; Petronek MS; Bodeker KL; Vollstedt S; Brown HA; Opat E; Hollenbeck NJ; Shanks T; Berg DJ; Smith BJ; Smith MC; Monga V; Furqan M; Howard MA; Greenlee JD; Mapuskar KA; St-Aubin J; Flynn RT; Cullen JJ; Buettner GR; Spitz DR; Buatti JM; Allen BG; Magnotta VA
    Redox Biol; 2021 Jan; 38():101804. PubMed ID: 33260088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.